Für Ärzte/Ärztinnen

Hier gibt es Unterstützung für die Betreuung Ihrer Reizdarm-Patienten:


Ein SIBO-Atemtest sollte Ihnen und Ihren Patienten individuelle und differenzierte Testergebnisse liefern, gemäß aktuellster wissenschaftlicher Erkenntnisse und unter Einbeziehung der Expertise international führender SIBO-Ärzte!


Ergänzende Links zu Studien und anderen Dokumenten:

 

Aus Zeitgründen habe ich seit einiger Zeit keine neueren Studien gelistet - es gibt aber inzwischen eine Vielzahl an zusätzlichen Untersuchungen zu den u.g. Themenbereichen.

REIZDARM

 

Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome (IBS).

https://www.ncbi.nlm.nih.gov/pubmed/30611316

 

A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.

https://www.ncbi.nlm.nih.gov/pubmed/30406392

 

Launch of ibs-smart™, an advancement in blood testing for Irritable Bowel Syndrome (IBS) 

https://www.prnewswire.com/news-releases/launch-of-ibs-smart-an-advancement-in-blood-testing-for-irritable-bowel-syndrome-ibs-announced-by-gemelli-biotech-in-partnership-with-the-medically-associated-science-and-technology-program-mast-at-cedars-sinai-300728775.html

 

Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

https://www.ncbi.nlm.nih.gov/pubmed/28451914

 

Cedars-Sinai Research Identifies Gut Gas Linked to Diarrhea (Hydrogen Sulfide)

https://www.cedars-sinai.org/newsroom/cedars-sinai-research-identifies-gut-gas-linked-to-diarrhea/

 

Review of rifaximin as treatment for SIBO and IBS

https://www.ncbi.nlm.nih.gov/pubmed/19243285

 

Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/29508268

 

Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/

 

Update on Irritable Bowel Syndrome Diagnostics and Therapeutics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/

 

IBSchek - The First Clinically Validated Blood Test for IBS with Predominant Diarrhea (IBS-D) and Mixed Symptoms (IBS-M)

http://www.commdx.com/irritable-bowel-syndrome.html

 

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/11151884/

 

25 % aller Nicht-Antibiotika schädigen Darmbakterien

https://www.ernaehrungsmedizin.blog/2018/03/20/hunderte-medikamente-schaedigen-darmbakterien/

 

Proton pump inhibitors (PPI) therapy and risk of C. diff. infection: Systematic review and meta-analysis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643276/

 

FODMAP

 

Kluyveromyces marxianus-Hefe ermöglicht die Herstellung von FODMAP-armem Vollkornbrot

https://www.ncbi.nlm.nih.gov/pubmed/30166134

 

Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs

https://www.ncbi.nlm.nih.gov/pubmed/28740352

 

Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467063/

 

Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918736/

 

A diet low in FODMAPs reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/24076059

 

Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/21615553

SIBO

 

A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.

https://www.ncbi.nlm.nih.gov/pubmed/30406392

 

Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/29508268

 

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

https://www.ncbi.nlm.nih.gov/pubmed/21208106

 

Treatment of SIBO

http://www.townsendletter.com/FebMarch2015/sibo0215_2.html 

 

Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/

 

How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach

https://www.ncbi.nlm.nih.gov/pubmed/26780631

 

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/11151884/

 

Review of rifaximin as treatment for SIBO and IBS

https://www.ncbi.nlm.nih.gov/pubmed/19243285

 

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504364/

 

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

https://www.ncbi.nlm.nih.gov/pubmed/20852272

 

A 14-day elemental diet is highly effective in normalizing the lactulose breath test

https://www.ncbi.nlm.nih.gov/pubmed/14992438

 

Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/22523730

 

Two Independent Networks of Interstitial Cells of Cajal Work Cooperatively with the Enteric Nervous System to Create Colonic Motor Patterns

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153851/

 

Update on Irritable Bowel Syndrome Diagnostics and Therapeutics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/

 

Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/20937045

 

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system (also known as Saccharomyces cerevisiae HANSEN CBS 5926)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027949/

Download
ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth SIBO 2020
ACG_Clinical_Guideline__Small_Intestinal
Adobe Acrobat Dokument 406.0 KB
Download
Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
Repeat Rifaximin.pdf
Adobe Acrobat Dokument 258.8 KB
Download
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus
Breath Testing - North American Consensu
Adobe Acrobat Dokument 223.5 KB
Download
Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth
Rifaximin.pdf
Adobe Acrobat Dokument 387.3 KB
Download
A Combination of Rifaximin and Neomycin Is Most Effective in Treating Irritable Bowel Syndrome Patients With Methane on Lactulose Breath Test
Rifaximin - Neomycin.pdf
Adobe Acrobat Dokument 132.1 KB
Download
Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth
Herbal Antibiotics - Rifaximin.pdf
Adobe Acrobat Dokument 1.0 MB
Download
A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test
Elemental Diet.pdf
Adobe Acrobat Dokument 156.2 KB
Download
Low-Dose Nocturnal Tegaserod or Erythromycin Delays Symptom Recurrence After Treatment of Irritable Bowel Syndrome Based on Presumed Bacterial Overgrowth
Prokinetics for SIBO.pdf
Adobe Acrobat Dokument 290.6 KB
Download
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders
Prokinetic LDN.pdf
Adobe Acrobat Dokument 4.1 MB
Download
Systematic Review: Cardiovascular Safety Profile of 5-HT4 Agonists Developed for Gastrointestinal Disorders
Prokinetic Prucalopride.pdf
Adobe Acrobat Dokument 267.4 KB
Download
Dr. Siebeckers Behandlungsschema (Mai 2018)
Siebeckers-Behandlungsschema-05-05-18_de
Adobe Acrobat Dokument 2.4 MB
Download
Dr. Siebeckers Vorschläge zur Symptomlinderung
Siebecker_sibo_symptomatic_relief_sugges
Adobe Acrobat Dokument 197.6 KB

METHANOGENE

 

Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath

https://www.ncbi.nlm.nih.gov/pubmed/22573345

 

Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909102/

Download
A new term for methanogens rather than SIBO: Intestinal Methanogen Overgrowth (IMO)
ACG_Clinical_Guideline__Small_Intestinal
Adobe Acrobat Dokument 406.0 KB

HYDROGENSULFID   (Flat-Line Test Results / "Non-Responder")

 

Hydrogen Sulfide Dysbiosis: A Case Study ("Flat Line" Breath Test Result)

https://ndnr.com/gastrointestinal/hydrogen-sulfide-dysbiosis-a-case-study/

 

Hydrogen sulphide in exhaled breath: a potential biomarker for small intestinal bacterial overgrowth in IBS.

https://www.ncbi.nlm.nih.gov/pubmed/27163246

 

Cedars-Sinai Research Identifies Gut Gas Linked to Diarrhea (Hydrogen Sulfide)

https://www.cedars-sinai.org/newsroom/cedars-sinai-research-identifies-gut-gas-linked-to-diarrhea/

 

Download
Phenotype and Antibiotic Response in Patients With Flat Line Breath Test Results: A Large Scale Database Analysis
Flat Line Breath Test Result.pdf
Adobe Acrobat Dokument 633.9 KB

SIFO (Small Intestinal Fungal Overgrowth)

 

Download
SIFO - A Cause of Gastrointestinal Symptoms (AGA Gastroenterology)
SIFO - A Cause of Gastrointestinal Sympt
Adobe Acrobat Dokument 693.1 KB

BIOFILM

 

Biofilm formation of mucosa-associated methanoarchaeal strains

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086402/

 

Biofilms: What Have We Learned from the Research?

http://ndnr.com/gastrointestinal/biofilms-what-have-we-learned-from-the-research/

 

Candida Biofilms: Threats, Challenges, and Promising Strategies

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816785/

 

Candida glabrata Biofilms: How Far Have We Come?

https://www.mdpi.com/2309-608X/3/1/11/htm

Download
Discussion about the issues surrounding biofilm therapies, Discussion of the safe uses of biofilm Tx with Rx
Dr Anderson re Biofilm-05-31-2016.pdf
Adobe Acrobat Dokument 207.0 KB

CANDIDA

 

Candida Biofilms: Threats, Challenges, and Promising Strategies

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816785/

 

Plants’ Natural Products as Alternative Promising Anti-Candida Drugs

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628516/

 

Candida glabrata Biofilms: How Far Have We Come?

https://www.mdpi.com/2309-608X/3/1/11/htm

MCAS (Mastcell Activation Syndrome)

 

What is Mast Cell Activation Syndrome (MCAS)?

https://www.drtaniadempsey.com/mastcellactivationsyndrome

 

Ein Webinar von Dr. Afrin (in Englisch) zum Thema MCAS gibt es am Seitenende der folgenden Website:

https://www.drtaniadempsey.com/aboutdrafrin

 

Characterization of Mast Cell Activation Syndrome

https://www.ncbi.nlm.nih.gov/pubmed/28262205

 

Meilenstein in der Diagnostik von Mastzellerkrankungen

https://www.ukb.uni-bonn.de/42256BC8002AF3E7/vwWebPagesByID/27D4C009920E64E6C12571FD003AF0D8

 

Fragebogen Mastzell-Erkrankungen - Patientenversion

https://www.humangenetics.uni-bonn.de/de/forschung/forschungsprojekte/mastzellerkrankungen/checklistepatientenversion

 

Full List of Publications and Presentations by Lawrence B. Afrin, M.D.

http://mastcellresearch.com/full-list-of-publications-and-presentations-by-lawrence-b-afrin-md/

Dr. Theoharis C. Theoharides

https://www.mastcellmaster.com/

 

The Mastocytosis Society

https://www.tmsforacure.org/